Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting. J of Skin [Internet]. 2026 Mar. 10 [cited 2026 May 1];10(2):s730. Available from: https://skin.dermsquared.com/skin/article/view/4039